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Abstract 
Introduction: Pretargeted radioimmunoimaging and -therapy approaches building on the 
bioorthogonal inverse-electron-demand Diels-Alder (IEDDA) reaction between strained trans-
cyclooctenes (TCO) and electron-deficient tetrazines (Tz) have yielded impressive results in recent 
years and have proven a vital alternative to biological pretargeting systems. After improvement of 
the TCO-antibody conjugates, we here report on our evaluation of a new series of radiolabeled Tz-
probes. 
Methods: Four new Tz-probes were synthesized, radiolabeled with lutetium-177, and characterized 
in vitro in terms of lipophilicity, reactivity, and stability in PBS and mouse serum. The in vivo 
biodistribution profile and tumor-targeting potential of the probes was evaluated in LS174T tumor-
bearing mice pretargeted with TCO-antibody conjugates using non-pretargeted mice as control. 
Results: Radiolabeling of all probes proceeded in high yields providing the 
177
Lu-labeled tetrazines 
in >95% radiochemical purity without any further purification. In mouse serum, half-lives of the 
probes varied between 8 and 13 h, with the exception of the most lipophilic probe, [
177
Lu]1b, with a 
serum half-life of less than 1 h. This probe also showed the fastest blood clearance (t1/2 = 5.4 min), 
more than 2-fold faster than PEG-linked probes [
177
Lu]3 and [
177
Lu]4, and even 3-fold faster than the 
other small probes without the PEG-linker, [
177
Lu]1a and [
177
Lu]2. In the pretargeting experiments, 
tumor uptake of the lead probe [
177
Lu]4 (~6 %ID/g) was most closely approached by [
177
Lu]2, 
followed by [
177
Lu]3 and [
177
Lu]1a. While all the smaller and more lipophilic probes suffered from 
increased liver uptake, the PEG-linked probe [
177
Lu]3 with its additional negative charge surprisingly 
showed the highest kidney uptake among all of the probes. 
Conclusion: The in vitro performance of some of the new tetrazine probes turned out to be 
comparable to the established lead probe [
177
Lu]Lu-DOTA-PEG11-Tz ([
177
Lu]4). However, tumor 
pretargeting studies in vivo showed lower tumor uptake and increased uptake in non-target organs. 
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1.  Introduction 
After FDA approval of the first agents ibritumomab tiuxetan (Zevalin) and iodine tositumomab 
(Bexxar) more than a decade ago, radioimmunotherapy (RIT) is well established as a second-line 
therapy for treatment of refractory non-Hodgkins lymphoma [1]. One of the major limitations of 
conventional RIT with radiolabeled monoclonal antibodies (mAbs) is the high radiation dose to non-
target tissues resulting from the combination of prolonged blood clearance and slow target uptake 
(reviewed in [2]). Pretargeted radioimmunotherapy (PRIT) addresses this issue by combining the 
superior targeting properties of antibodies with the favorable pharmacokinetics of smaller molecules 
(reviewed in [3, 4]). The method relies on tumor pretargeting with engineered mAbs having both 
affinity for a tumor-associated antigen and the capability to bind to a radioligand. The fast-clearing 
radioligand is then injected in a second step, after allowing sufficient time for accumulation of the 
mAbs in the tumor and clearance from blood. Currently, two pretargeting approaches have been 
clinically validated: bispecific antibodies with affinity for both the tumor and the radiolabeled small 
hapten [5], and antibody-conjugates making use of the streptavidin-biotin interaction [6]. While the 
first system requires extensive reengineering and perturbation of the parent mAb, streptavidin-biotin 
systems frequently suffer from immunogenicity, thereby precluding repeated treatment cycles [7]. 
Recently developed chemical pretargeting strategies relying on antibody modification with small tags 
may hold the potential to circumvent these issues (reviewed in [8, 9]). Among several bioorthogonal 
chemical reactions evaluated for this purpose, the inverse-electron-demand Diels-Alder (IEDDA) 
reaction between strained trans-cyclooctenes (TCO) and electron-deficient tetrazines (Tz) has 
yielded promising results for pretargeted radioimmunoimaging and –therapy in preclinical studies 
[10-19], whereas the Staudinger ligation and the strain-promoted alkyne-azide cycloaddition reaction 
(SPAAC) suffered from a number of limitations [20-22]. Following our initial report on pretargeted 
tumor imaging in live mice using a TCO-antibody conjugate and an 
111
In-labeled Tz-probe (Fig. 1) 
[10], we and others have continuously improved the system by developing more reactive TCO-tags 
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with increased in vivo stability [14] and dedicated Tz-probes for radiolabeling with copper-64 [12], 
gallium-68 [23], fluorine-18 [17, 24], carbon-11 [25, 26], technetium-99m [27], and iodine-125 [28]. 
In the meantime, Tz-probes with reduced gastrointestinal clearance have shown promise for 
pretargeted immuno-PET of colorectal cancer [16, 18] and radioimmunotherapy of pancreatic ductal 
adenocarcinoma [19] in preclinical studies. To further increase tumor-to-blood ratios and maximize 
tumor dose in pretargeted radioimmunotherapy, we have introduced a rapid bioorthogonal chemical 
clearing approach for removal of residual circulating TCO-conjugated antibodies from blood prior to 
injection of the radiolabeled probe [13]. Finally, our efforts resulted in an optimized pretargeting 
protocol employing antibody constructs with a more reactive and less hydrophobic TCO-tag with 
higher in vivo stability, and improved tumor accumulation [15].  
Having optimized the reactivity and pharmacokinetics of the TCO-tagged antibody, in this work, we 
set out to explore the parameters that govern in vivo performance of the tetrazine probe, which may 
in the future enable the design of a probe with improved tumor uptake and reduced uptake in the 
kidney, the organ retaining most of the activity apart from the tumor [13]. Inspired by earlier 
investigations suggesting that an increase of negative charges in DOTA- and DTPA-conjugated 
peptides resulted in reduction of renal uptake [29, 30], we designed a Tz-probe 3 (Fig. 2), in which 
the Tz-moiety is attached via a PEG10-thioureabenzyl-linker to the carbon backbone of the DOTA, 
allowing for as many as four carboxymethyl functionalities and resulting in a net negative charge of 
the 
177
Lu-labeled probe at physiologic pH. Aiming at probes with better tumor penetration and a 
more homogenous uptake, we created the shorter Tz-DOTA derivatives 1a and 1b linked by straight 
chain C6- and C11-amidoalkyl groups, respectively, and probe 2, which in fact corresponds to the 
original probe 4 without the PEG-spacer (Fig. 2). The new probes were evaluated in vitro and in vivo 
employing our previously developed clearing agent strategy [13] and pretargeting components (Fig. 
2), and benchmarked against lead probe 4.   
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2.  Experimental 
 
2.1.  Chemistry 
Synthetic procedures and spectral data for the new Tz-probes 1a/b, 2, 3, and 4 are described in §1 and 
§2 of the Supplemental Information associated with this article. Preparation of CC49-TCO (6) and 
galactose-albumin-tetrazine (5) has been reported elsewhere [10, 13].  
 
2.2.  Radiochemistry 
Radioiodination of CC49-TCO (6) was performed with the Bolton-Hunter method, followed by 
purification and quality control according to a published procedure [13]. A detailed procedure 
including results is also reported in § 3.1 of the Supplemental Information. For animal experiments, 
the specific activity of the [
125
I]I-CC49-TCO was adjusted to 2–5 kBq/μg by adding nonradioactive 
CC49-TCO.  
The DOTA-conjugated Tz-probes 1a/b, 2, 3, and 4 were dissolved in 0.2 M ammonium acetate pH 
7.0 at concentrations of 1-2 mg/mL and stored at –80°C before use. Radiolabeling for the in vitro 
stability studies was performed by combining suitable volumes of probe stock solutions 
(corresponding to 10 μg for tetrazine 1a/b and 2, 15 μg for tetrazine 3 and 4) with [177Lu]LuCl3 (20 – 
35 MBq; Perkin-Elmer) in 0.2 M ammonium acetate pH 5.5 (total volume of the reaction mixture 
was 20 μL) and incubating at 60°C for 5 min in a thermomixer (350 rpm). Following addition of 5 
μL of 10 mM diethylenetriaminepentaacetic acid (DTPA) and incubation for another 5 min at 60°C, 
radiochemical yield and purity were assessed by radio-iTLC and radio-HPLC, respectively. Molar 
activities (Am) for the 
177
Lu-labeled Tz-probes 1a, 1b, 2, 3, and 4 were 2.28 ± 0.21, 2.54 ± 0.65, 2.02 
± 0.42, 2.85 ± 0.28, and 2.62 ± 0.40 MBq/nmol, respectively (n = 6 for each probe). For investigation 
of the in vitro reaction kinetics, labeling was performed according to the same procedure, but at 
higher specific activity (50 – 60 MBq [177Lu]LuCl3, 5 μg tetrazine, i.e., As ~ 10 – 12 MBq/μg), and 
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gentisic acid (20 μL of a 20 mg/mL solution in 0.9% saline - 1.0 M Na2CO3, 9:1) was added post-
labeling to prevent autoradiolysis.  
For the in vivo studies, the tetrazines were labeled to a molar activity (Am) of 0.11 – 0.15 MBq/nmol 
by combining a suitable volume of the Tz-stock solutions with [
177
Lu]LuCl3 in 1.0 M NH4OAc pH 
5.0 (10 μL) and incubating at 60°C for 5 min, followed by addition of gentisic acid (50 μL of a 20 
mg/mL solution in 0.9% saline - 1.0 M Na2CO3, 9:1) and 10 mM DTPA (5 μL). After incubation at 
60°C for another 5 min, aliquots of the labeling mixture were analyzed by radio-TLC and radio-
HPLC, and the reaction mixture diluted with sterile 0.9% saline for animal experiments, each dose 
(80 μL, ca. 1 MBq) containing 6.67 nmol of tetrazine and 100 μg of gentisic acid.  
 
2.3. In vitro characterization of radiotracers 
2.3.1. Distribution coefficient LogD7.4 in 1-octanol / PBS pH 7.4 
LogD7.4 values were measured using the shake flask method. Tetrazines were radiolabeled according 
to the protocol for the in vitro studies, however, apart from [
177
Lu]LuCl3, also non-radioactive LuCl3 
(0.8 eq. with respect to probe) was added to the labeling mixture. The labeled tetrazines were 
additionally purified by passing through a C8 Sep-Pak
®
 cartridge and eluting with ethanol, mainly to 
remove traces of highly polar [
177
Lu]LuDTPA. To 1-octanol (0.5 mL) and PBS pH 7.4 (0.5 mL), 
which had been pre-saturated with each other, was added 5 μL of the purified ethanolic radiotracer 
stock solution (about 1 MBq, radiochemical purity >95%, radio-HPLC), and the phases were 
thoroughly mixed using a vortex (3 × 30 sec) then incubated at room temperature in a thermomixer 
(550 rpm) for 5 min. This procedure was repeated twice to establish a stable equilibrium between the 
phases. Following phase separation by centrifugation in an eppendorf centrifuge at 16,100 × g for 5 
min, aliquots of both phases (3 × 25 μL for the aqueous phase, 3 × 100 μL for the organic phase) 
were counted in a γ-counter (Wizard 1480; Perkin Elmer). LogD7.4 was calculated as log [(cpm in 
octanol) / (4 × cpm in PBS)]. For each probe, all determinations were performed in triplicate.  
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2.3.2. Radiotracer stability in PBS pH 7.4 and in mouse serum 
The 
177
Lu-labeled Tz-probes 1a/b, 2, 3, and 4 were incubated at 37°C under gentle agitation (350 
rpm) in either PBS pH 7.4 or 50% mouse serum/PBS (Balb/C mouse serum, purchased from 
Innovative Research, and filtered through a 0.45 μm PTFE syringe filter before use) at a 
concentration of 4.8 nmol/mL (corresponding to the concentration in blood achieved after i.v. 
injection of the probes in the animal experiments) and activity concentrations of 10 – 15 MBq/mL. 
For the PBS-incubation, aliquots were directly analyzed by radio-HPLC immediately after addition 
and mixing, and after 0.5, 1, 2, 4, and 20 h. For the serum samples, 100 μL aliquots were retrieved at 
the same time points, thoroughly mixed with an equal volume of ice-cold acetonitrile, and proteins 
separated by centrifugation (16,100 × g, 5 min). An aliquot of the supernatant was removed for 
radio-HPLC, and another aliquot (50 μL) for measuring of radioactivity in the supernatant. The 
remaining supernatant was discarded, and radioactivity of the pellet and supernatant-aliquot 
determined in a γ-counter for quantification of probe binding to serum proteins. To eliminate any 
effects due to sample processing, stability values (% intact radiotracer) were reported relative to the 
control sample (t = 0), for which the amount of intact probe was set to 100%. All determinations (for 
each probe and each time point) were performed in triplicate. Serum stability half-lives were 
calculated from a one-phase exponential decay fit of the data.  
 
2.3.3. Reaction kinetics between CC49-TCO and 
177
Lu-labeled Tz-probes 
The Tz-probes 1a/b, 2, 3, and 4 were radiolabeled at high specific activity (10 MBq/μg) as described 
above. Directly before the experiment, a weighted aliquot of a CC49-TCO 6 stock solution (8.8 
TCO/mAb) was diluted with pre-warmed (37°C) 50% mouse serum / PBS pH 7.4 (filtered Balb/C 
mouse serum) to yield a final mAb-concentration of 10 μg/mL in a volume of about 1 mL 
(corresponding to a TCO-concentration of 587 nM). The reaction was started by addition of the 
177
Lu-labeled Tz (several μL of a 10 – 20 fold diluted radiolabeling mixture) to give a final 
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concentration of 29 nM (1/20
th
 of TCO-concentration) in the reaction mixture. After thorough 
mixing, 20 μL samples of the reaction mixture were withdrawn at selected times (15, 30, 45, 60, 120, 
and 300 sec) and quenched with an excess of non-radioactive tetrazine. Aliquots of each reaction 
mixture were analyzed by SDS-PAGE and phosphor imager and the cycloaddition yields were 
calculated from the radioactivity in the bands corresponding to the unreacted and mAb-bound 
177
Lu-
labeled tetrazine (Supplemental Information, § 3.3, Figure S6 and S7). The pseudo first-order rate 
constants (kobs) were determined from the fits to a first-order exponential. 
 
2.4.  Animal studies 
Mice were housed and handled according to institutional guidelines complying with European 
legislation and the Dutch national law “Wet op de Dierproeven” (Staatsblad 1985, 336). Approval of 
the animal welfare committee of Maastricht University (the Netherlands) was obtained prior to the 
commencement of the studies. Animals were kept in a temperature-controlled environment with a 
12-hour light/12-hour dark cycle. They received a standard diet (Sniff R/M-H, Sniff Spezialdiäten 
GmbH, Soest, The Netherlands) and acidified water ad libitum. The human colon cancer cell line 
LS174T was obtained from ATCC and maintained in Eagle’s minimal essential medium (Sigma) 
supplemented with 10% heat inactivated fetal calf-serum (Gibco), penicillin (100 U/mL), 
streptomycin (100 μg/mL) and 2 mM Glutamax. Female nude Balb/C mice (18 – 23 g body weight; 
Charles River Laboratories) were inoculated subcutaneously with 5 × 10
6
 LS174T cells in 100 μL of 
sterile PBS, and were used when the tumors had reached a size of 70–250 mm3 (typically after 7–10 
days). Tumor weights at the time of biodistribution were 0.28 ± 0.11 g (mean ± SD). Sample 
radioactivity was measured in a γ-counter (Wizard 1480, Perkin Elmer) using either a single-isotope 
protocol with an energy window of 10–380 keV for lutetium-177, or a dual-isotope protocol with 
energy windows of 10–80 keV and 155–380 keV for iodine-125 and lutetium-177, respectively, with 
cross contamination correction. Radioactivity of the biodistribution samples was counted along with 
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standards to determine the percentage of injected dose (%ID) per gram of tissue and per organ. The 
%ID/organ values for stomach, small and large intestines relate to organ including content. 
 
2.4.1. Dual-isotope biodistribution experiments in pretargeted mice 
Four groups of tumor-bearing mice (n = 3–4) were intravenously injected with 125I-labeled CC49-
TCO (6) (average of 7 TCOs/mAb; 100 μg in 100 μL of saline per mouse; 0.20–0.45 MBq), followed 
by two doses of clearing agent (5) (160 μg in 100 μL of saline per dose) after 30 h and 48 h. Two 
hours after the last clearing agent injection, each group of mice was injected with one of the different 
177
Lu-labeled Tz-probes 1a/b, 2, 3, and 4 (per dose: 6.7 nmol tetrazine in 80 μL of saline containing 
100 μg of gentisic acid; 0.6–1.0 MBq). Mice were euthanized 3 hours after [177Lu]Lu-tetrazine 
injection, blood was withdrawn, tissues and organs of interest were collected, blotted dry, weighted, 
combined with 1 mL of PBS, and counted in a γ-counter (dual-isotope protocol).   
 
2.4.2. Tetrazine blood clearance and biodistribution in non-pretargeted tumor-bearing mice 
Each of four groups of tumor-bearing mice (n = 3–4) was intravenously injected with one of the 
different 
177
Lu-labeled Tz-probes 1a/b, 2, 3, and 4 (per dose: 6.7 nmol tetrazine in 80 μL of saline 
containing 100 μg of gentisic acid; 0.6–1.0 MBq). Mice were serially bled at selected time points (2, 
5, 10, 20, 40, and 60 min post probe injection; ca. 20 μL per time point), and euthanized 3 hours after 
[
177
Lu]Lu-Tz injection. Blood was withdrawn, tissues and organs of interest were collected, and 
radioactivity was measured in a γ-counter (single-isotope protocol).   
 
2.5.  Data analysis 
Unless stated otherwise, all data are reported as mean ± standard deviation (SD). Curve fitting and 
calculation of rate constants, half-lives, and two-tailed unpaired t tests were performed with 
GraphPad Prism version 6.05. 
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3. Results and discussion 
 
3.1.  Synthesis of tetrazine probes and radiolabeling  
Tetrazine-n-alkyl-DOTA probes 1a and 1b were assembled from 2-cyanopyridine, hydrazine and N-
Boc-protected 2-cyano-5-amidoalkylaminopyridines 7a and 7b, which had been obtained in two 
steps from the corresponding straight-chain alkylaminocarboxylic acids and 2-cyano-5-
aminopyridine (Fig. 3). After oxidation with sodium nitrite, Boc-deprotection with TFA, and 
coupling to DOTA-mono-(N-hydroxysuccinimide)-ester, the target compounds were obtained in 
overall yields of 25% and 14%, respectively. Compound 2, a shorter version of lead compound 4 
without the PEG-spacer, was prepared from tetrazine 11 by coupling with 2-aminoethyl-mono-
amide-DOTA-tris-tBu-ester 12 followed by tBu-deprotection with TFA (Fig. 3, bottom left). The 
PEG10-thioureabenzyl-linked compound 3 with four carboxymethyl functionalities, finally, was 
readily accessible from tetrazine 14, a common precursor in the synthesis of lead compound 4, which 
after Boc-deprotection is coupled to 2-(p-isothiocyanatobenzyl)-DOTA 15 (Fig. 3, bottom right).  
The HPLC-purified probes were conveniently radiolabeled with lutetium-177 at 60ºC in minutes 
with radiochemical yields typically exceeding 98%. Radiochemical purity after DTPA challenge was 
always >95%, allowing direct use of the labeling mixtures for the in vivo and in vitro studies without 
any further purification. 
 
3.2. Probe evaluation in vitro 
The physicochemical properties of the Tz-probes are summarized in Table 1, together with their in 
vitro stability data in PBS and 50% mouse serum/PBS, and their reactivity towards the TCO-tagged 
antibody CC49 6, expressed as pseudo first-order rate constants kobs. In addition, HPLC metabolite 
profiles and comprehensive stability data for all time points (0.5, 1, 2, 4 h, and 20 h) are provided in 
the Supplemental Tables S1, S2, and S3.  
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The hydrophilic PEG-linked probes [
177
Lu]3 and [
177
Lu]4 display very similar profiles with stability 
half-lives at 37ºC of about 25 h in PBS and 8 h in 50% mouse serum. Both probes were primarily 
degraded to slightly more polar metabolites eluting about 1 – 2 min before the parent probe on radio-
HPLC. Interestingly, HPLC-retention time (Rt) of the main metabolite after incubation in 50% serum 
was different (about 1 min shorter) than retention time of the main metabolite after incubation in 
PBS, suggesting different species are formed in these media (Supplemental Information, § 3.2, 
Tables S1 and S2, and Figures S4 and S5). Furthermore, incubation in PBS resulted in a higher level 
of highly hydrophilic metabolites (Rt ~ 2 – 2.5 min), presumably arising from cleavage of the 
[
177
Lu]LuDOTA group. Nevertheless, even after incubation in PBS, these highly hydrophilic species 
generally account for less than 20% of the total metabolites, while the remaining >80% are 
consisting of the main metabolites mentioned above. The smaller and slightly less hydrophilic probes 
[
177
Lu]1a and [
177
Lu]2 turned out to be more stable, particularly in 50% mouse serum ([
177
Lu]1a: t1/2 
= 11.3 h; [
177
Lu]2: t1/2 = 13.4 h). Different from the PEG-linked probes [
177
Lu]3 and [
177
Lu]4, 
however, serum incubation of [
177
Lu]1a and [
177
Lu]2 mainly yielded the highly polar metabolite 
eluting with Rt = 2.5 min on radio-HPLC (accounting for >80% of total metabolites). Probe 
[
177
Lu]1b, finally, a close analog of [
177
Lu]1a with double length of the alkyl linker and substantially 
increased lipophilicity, proved to be the least stable of all probes, with a half-life in 50% serum/PBS 
of less than one hour and clean degradation into a single slightly more polar metabolite (HPLC, Rt = 
10.6 min). All probes only showed a low degree of serum protein binding (Supplemental Table S2) 
ranging from 5.6 ± 1.2% (n = 3, 30 min incubation time) for lead probe [
177
Lu]4 to 10.4 ± 3.4% (n = 
3) for [
177
Lu]1b, the most lipophilic probe in the series. 
Apart from probe stability, also the relative reactivity of the 
177
Lu-labeled Tz-probes towards the 
mAb-bound TCOs and the Tz-pharmacokinetics, particularly blood clearance, are important 
parameters impacting tumor uptake. Even though all probes contain the same bis-(2-pyridyl)-1,2,4,5-
tetrazine group, we have nevertheless determined the relative reaction rates of the Tz-probes (Table 
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1), and have found differences in reactivity. [
177
Lu]1b, the least stable probe with the fastest blood 
clearance, turned out to be the most reactive, followed by [
177
Lu]1a, its more hydrophilic analog with 
shorter alkyl-linker. The remaining probes, [
177
Lu]2 and [
177
Lu]3, showed pseudo first-order rate 
constants (kobs) similar to the lead probe [
177
Lu]4. Importantly, “enforced hydrophobic interactions” 
have been suggested to provide an additional driving force for the IEDDA reaction due to reduction 
of the solvent-exposed hydrophobic surface area of the reactants in aqueous media [31, 32]. Along 
this line, increasing lipophilicity of the IEDDA reaction partners may result in higher reaction rates, 
and it is not surprising that the most hydrophobic 
177
Lu-labeled Tz-probes in the series, [
177
Lu]1a and 
[
177
Lu]1b in particular, indeed displayed the highest kobs in serum.  
 
3.3. Comparative in vivo study: Tumor uptake, biodistribution, and blood clearance  
The new Tz-probes were evaluated in vivo and benchmarked against lead probe 4 employing our 
previously established pretargeting protocol based on the TAG-72 targeting mAb CC49 conjugated 
to axially substituted TCO tags via oxymethylbenzamide linkages (CC49-TCO 6, Fig. 2) [14] and a 
bioorthogonal clearing agent strategy [13]. Briefly, CC49-TCO 6 was radiolabeled with iodine-125 
via the Bolton-Hunter method (isolated radiochemical yield after purification 22.4 ± 7.3%, n = 5, 
radiochemical purity >99%, detailed data in Supplemental Information, § 3.1), and intravenously 
administered to LS174T tumor-bearing mice (n = 3–4 per group), followed by two doses of clearing 
agent 5, 30 and 48 h post mAb injection, and finally the 
177
Lu-labeled tetrazines two hours after the 
last clearing agent injection. Dual-isotope biodistribution data 3 h post tetrazine injection are 
summarized in Table 2.  
For comparison, control experiments were performed in non-pretargeted LS174T tumor-bearing 
mice (n = 3–4 per group), which only received 177Lu-labeled tetrazines and were sacrificed 3 h post 
injection. Selected biodistribution data from these experiments are reported in Table 3. In addition, 
blood-clearance half-lives (Table 1 and Supplemental Table S6) were calculated from one-phase 
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exponential decay fits of blood radioactivity data from blood-sampling (Fig. 4). While [
177
Lu]3 
displayed comparable blood kinetics to lead probe [
177
Lu]4, the smaller probes [
177
Lu]1a and 
[
177
Lu]2 were retained in blood for longer time periods (t1/2 ≈ 18 min), and the most lipophilic probe 
[
177
Lu]1b was eliminated from blood with a blood clearance half-life of 5.4 min, 2-fold faster than 
lead probe [
177
Lu]4 (Table 1). On a general note, all blood clearance data are based on total blood 
radioactivity and do not distinguish between the intact radiotracer and circulating metabolites (vide 
infra).  
In the pretargeting experiments (Table 2), tumor uptake of the new Tz-probes varied considerably, 
but all of them showed lower uptake than lead probe [
177
Lu]4. Tumor targeting of the lead probe was 
most closely approached by [
177
Lu]2, a shorter version of this probe without the PEG-spacer. 
However, [
177
Lu]2 also displayed an almost 15-fold higher liver uptake, while at the same time not 
leading to significantly reduced uptake in the kidney. With a 2-atom shorter linker without the 
additional amide group, the structurally closely related probe [
177
Lu]1a resulted in an almost 3-fold 
higher liver uptake compared to [
177
Lu]2 alongside with a 50% lower tumor uptake. Doubling the 
length of the alkyl-linker from a pentyl-group in [
177
Lu]1a to a decyl-group in probe [
177
Lu]1b led to 
a dramatic increase in liver uptake up to almost 14% ID/g and a concomitant decrease in tumor 
uptake down to only about 1% ID/g, which is presumably associated with the significantly shorter 
blood elimination half-life of this probe. 
On a general note, as expected, increasing probe lipophilicity appears to correlate with a higher liver 
uptake, with the hydrophilic probes [
177
Lu]3 and [
177
Lu]4 (both around 0.2% ID/g) at the lower 
range, [
177
Lu]2 (2.63 ± 0.30 %ID/g) and [
177
Lu]1a (6.73 ± 1.40 %ID/g) in the middle section, and the 
most lipophilic [
177
Lu]1b (13.63 ± 1.06 %ID/g) at the upper range of the scale (Table 2), covering 
lipophilicity differences of 4 orders of magnitude (Table 1). The high uptake in the liver and 
intestines, together with an almost 5-fold lower kidney uptake than lead probe [
177
Lu]4, suggest that 
[
177
Lu]1b is predominantly cleared via the hepatobiliary route. In contrast, the probes of intermediate 
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lipophilicity, [
177
Lu]1a and [
177
Lu]2, show a kidney uptake similar to lead probe [
177
Lu]4, pointing 
towards partial renal clearance of the probes alongside hepatobiliary excretion. Strikingly and in 
contrast to our expectations, the only negatively charged probe that we have studied, the PEG10-
thioureabenzyl-linked probe [
177
Lu]3, displayed the highest kidney uptake within the series, more 
than 2-fold the uptake of lead probe [
177
Lu]4.  
Comparison of our findings with recently published data from 
64
Cu-labeled probes based on the 
related 3-4-(benzylamine)-1,2,4,5-tetrazine instead of our bis(pyridino)-system revealed similar 
trends [16]. Comparable to [
177
Lu]1a of the present work, the smallest probe in that study [16], a 
benzylamino-tetrazine moiety attached to a NOTA-chelator with a connecting C5-linker via amide 
bonds, is predominantly excreted via the gut with highest accumulation in the large intestines and its 
content and only low kidney uptake. Introduction of a PEG7-linker led to a probe with increased 
renal clearance and accelerated intestinal excretion, which correlates well with our results obtained 
for the PEG10-linked probes [
177
Lu]3 and [
177
Lu]4. 
Taken together, in the series [
177
Lu]1b  [177Lu]1a  [177Lu]2 of the smaller probes without PEG-
spacer, the decrease in probe lipophilicity and liver uptake apparently translates into a higher tumor 
uptake. Indeed, despite its almost 2-fold higher reactivity compared to lead probe [
177
Lu]4, the low 
tumor targeting potential of [
177
Lu]1b is not surprising given its short circulation half-life (t1/2 = 5.4 
min) and low stability in vitro (t1/2 in 50% serum < 1 h). For the other probes, however, there is no 
simple correlation between tumor uptake and reactivity, in vitro stability and in vivo blood clearance. 
In fact, [
177
Lu]1a and [
177
Lu]2 were expected to demonstrate superior tumor targeting, since these 
probes show the slowest blood elimination in vivo (t1/2 ≈ 18 min) the highest stability in vitro (t1/2 in 
50% serum >11 h), and a reactivity comparable or slightly superior to the lead probe [
177
Lu]4 (Table 
1). Apparently, the prediction of the in vivo behavior of the probes from their in vitro properties is 
not straightforward. The discrepancy between the in vivo and in vitro behavior may be related to a 
different metabolism of the probes in vivo. This issue has been described for a number of 
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radiopharmaceuticals, in particular radiopeptides, and has recently received considerable attention 
[33]. In vitro serum/blood incubation studies usually tend to overestimate the actual stability [33-37]. 
Moreover, in vivo metabolism may give rise to additional, structurally different metabolites than 
those identified in serum incubation studies in vitro [34]. While some of these metabolites may be 
identified by in vitro incubation studies using tissue homogenates (typically from liver and kidney as 
the main metabolizing organs), a true assessment of radiotracer metabolism and stability can often 
only be obtained from in vivo studies, among others due to the involvement of ectoenzymes on 
epithelial cells on various organs and tissues in the body [33, 34, 38]. Importantly, the radiotracer 
blood elimination curves (Fig. 4) only convey very limited information, as they are based on the total 
blood radioactivity, without any distinction between the intact radiotracer and circulating 
metabolites. Depending on their type and structure, most of the different 
177
Lu-labeled metabolites 
may not be reactive towards TCOs, resulting in a much lower probe bioavailability than suggested 
based on the non-metabolite-corrected radiotracer blood elimination curve. Unfortunately, in-depth 
investigation of probe bioavailability and characterization of metabolites requires a complete 
metabolism study, which is beyond the scope of this paper. Along these lines, it is not surprising that 
the slower blood clearance and higher in vitro stability of [
177
Lu]1a and [
177
Lu]2 compared to lead 
probe [
177
Lu]4 is not necessarily leading to an improved in vivo performance.   
Comparison of the biodistributions of the pretargeted and non-pretargeted mice (Table 2 versus 
Table 3) shows considerable agreement. Apart from [
177
Lu]1a, statistically significant differences 
were only found in the liver, kidney, or lung (Table 3). Evidently, the clearing agent strategy has 
proven effective, since the remaining level of [
125
I]I-CC49-TCO in the blood of pretargeted mice is 
too low to result in statistically significant differences between the blood values of the 
177
Lu-labeled 
tetrazines in pretargeted mice and non-pretargeted mice. At the same time, non-specific tumor uptake 
in the non-pretargeted group of mice (Table 3) was significantly lower than tumor uptake in the 
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pretargeted group of mice, which is in good agreement with the high level of [
125
I]I-CC49-TCO in 
the tumor (Table 2 and Supplemental Table S4). 
The lower tumor uptake of the new probes, together with increased uptake in most non-target tissues, 
translates into lower tumor-to-organ ratios, as expected (Fig. 5). In fact, perusal of Table 2 indicates 
that organ uptake values for all probes are higher than or about equal to lead probe [
177
Lu]4, the 
considerably lower kidney uptake of probe [
177
Lu]1b being the sole exception. However, even in this 
case, the reduction in kidney uptake proves not sufficient to compensate for the substantially lower 
tumor uptake of [
177
Lu]1b and still results in a lower tumor-to-kidney ratio compared to [
177
Lu]4. 
Although all new probes show lower tumor-to-blood ratios than lead probe [
177
Lu]4, the underlying 
reason is different; for [
177
Lu]1b it is mainly caused by the lower tumor uptake, while for [
177
Lu]1a 
and [
177
Lu]2, it is mainly determined by the higher blood uptake. Since blood retention of [
177
Lu]1a 
and [
177
Lu]2 is almost identical in the pretargeted and non-pretargeted groups of mice (Table 2 
versus Table 3), the higher blood retention of these probes compared to [
177
Lu]4 is presumably not 
related to reaction with residual circulating [
125
I]I-CC49-TCO, but is instead an intrinsic property of 
these probes and a result of slower blood clearance (Table 1) of the intact probes or their radioactive 
metabolites (vide supra). Indeed, the blood and tumor levels of [
125
I]I-CC49-TCO in the experiments 
described here (0.46 ± 0.18 %ID/g and 20.71 ± 3.37 %ID/g, Table 2) show a rather low variation 
between the groups (see Supplemental Table S4 for detailed data per group) and are comparable to 
previously reported values (0.19 ± 0.04 %ID/g and 22.22 ± 2.58 %ID/g, n = 4) [15], further 
supporting the conclusion that the higher blood and lower tumor levels of the new 
177
Lu-labeled 
tetrazines are mainly related to the probes and not to differences in the [
125
I]I-CC49-TCO 
biodistribution. Along this line, normalization of 
177
Lu-Tz tumor uptake to the individual [
125
I]I-
CC49-TCO uptake for each mouse led to almost identical values, but mostly smaller SD’s 
(Supplemental Table S5).  
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4.  Conclusion  
We have prepared a new series of tetrazine probes for application in pretargeted 
radioimmunoimaging and –therapy based on the inverse-electron-demand Diels-Alder reaction 
between strained trans-cyclooctenes and electron-deficient tetrazines. Apart from [
177
Lu]1b with an 
in vitro serum stability half-life of less than 1 h, all of the new tetrazine probes show similar or 
superior stability to lead probe [
177
Lu]4. At the same time, [
177
Lu]1b also turned out to be the most 
reactive probe in vitro, followed by its shorter C5-linker analogue [
177
Lu]1a, and finally the other 
probes, which demonstrated a reactivity comparable to the lead probe. In contrast to their in vitro 
performance, the in vivo profile of the new probes in tumor pretargeting studies did not meet our 
expectations. All of the probes showed lower tumor uptake than lead probe [
177
Lu]4 and were 
characterized by higher uptake in non-target organs, resulting in consistently lower tumor-to-organ 
ratios. While the smaller, more lipophilic probes particularly suffered from higher liver uptake, the 
negatively charged PEG-linked probe [
177
Lu]3 surprisingly showed the highest kidney uptake. 
Notably, the longer blood clearance half-lives and the increased serum stability of the small probes 
[
177
Lu]1a and [
177
Lu]2 (the best-performing probe beside the lead probe), did not translate into more 
effective tumor targeting. Further efforts towards the design of improved tetrazine probes should 
presumably focus on hydrophilic probes with significantly improved reactivity.  
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Figure Legends 
 
 
Fig. 1. Principle of tumor pretargeting with the inverse-electron-demand Diels–Alder (IEDDA) 
reaction between a trans-cyclooctene-tagged mAb and a radiolabeled tetrazine.  
 
Fig. 2. Chemical structures of new tetrazine probes (1a/b, 2, 3), lead probe 4, and schematic 
representation of clearing agent galactose-albumin-tetrazine (5) and trans-cyclooctene tagged CC49 
(6). 
 
Fig. 3. Synthetic strategy for preparation of new tetrazine probes 1a/b, 2, and 3. Reagents and 
conditions: (A) N2H4·H2O, S, EtOH, 70°C, o/n. Yields: 8a - 66%, 8b - 35%; (B) aq. NaNO2, AcOH/THF. 
Yields: 9a - 83%, 9b - 75%; (C) TFA, CHCl3, rt, 3 h; (D) DOTA-NHS, DIPEA, DMF, rt, 3 h. Yields over 2 
steps: 1a - 75%, 1b - 79%; (E) BOP, DIPEA, DMF, rt, 2 h, 44%; (F) TFA, CH2Cl2, rt, o/n (2×), 69%; (G) 
TFA, CH2Cl2, rt, 2 h; (H) DIPEA, DMF, rt, 2 h, 27% over 2 steps. 
 
Fig. 4. Blood clearance data of 
177
Lu-labeled tetrazines (6.7 nmol, 0.6 – 1.0 MBq) in non-pretargeted 
tumor-bearing mice, fitted to a one-phase exponential decay model. Data points represent the % 
injected dose per gram (%ID/g) and are mean ± SD (n = 4). For calculated half-lives, see Table 1. 
The complete raw data is provided in Supplemental Table S6. 
 
Fig. 5. Tumor-to-organ ratios from a biodistribution experiment of 
177
Lu-labeled tetrazines (1a, 1b, 
2, 3, and 4) in pretargeted LS174T tumor-bearing mice. The bar diagram is based on the 
experimental data reported in Table 2. Bars represent mean ± SD.
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Table 1 
Physicochemical properties, in vitro stability, reactivity and in vivo blood clearance of 
177
Lu-labeled Tz-probes 
Probe 
MW 
a)
 
(g/mol) 
LogD7.4 
mean ± SD  
Rt (min) 
b)
 
t1/2 (h) 
PBS 
c)
 
t1/2 (h) 
50% serum 
d)
 
kobs (×10
–2
 s
–1
) 
50% serum 
d)e) 
t1/2 (min) 
f)
 
Blood clearance
 
[
177
Lu]1a 750.8 – 2.65 ± 0.01 9.7 27.3 11.3 10.0 ± 0.3 18.0 
[
177
Lu]1b 820.9 – 0.42 ± 0.02 12.7 19.0 0.8 13.1 ± 0.8 5.4 
[
177
Lu]2 793.8 – 3.27 ± 0.02 9.2 27.8 13.4 7.3 ± 0.3 17.5 
[
177
Lu]3 1443.6 – 4.25 ± 0.08 11.4 24.7 7.7 6.2 ± 0.4 11.3 
[
177
Lu]4 1278.4 – 4.51 ± 0.07 11.1 25.8 8.4 7.5 ± 0.5 10.7 g) 
        
 
a)
 Molecular weight of the uncoordinated, metal-free probes.   
b)
 RP-HPLC retention times.    
c)
 PBS pH 7.4, 37ºC.   
d)
 50% mouse serum / PBS, 37ºC.   
e)
 Best-fit values (1
st
 order exponential) ± standard error.    
f)
 For 95% confidence intervals and the complete raw data, see Supplemental Table S6. 
g)
 Taken from reference [13] (in mice bearing LS174T tumor xenografts pretargeted with CC49-TCO (6). 
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Table 2  
Dual isotope biodistribution of [
125
I]I-CC49-TCO (6) and 
177
Lu-labeled tetrazines (1a, 1b, 2, 3, and 4) in 
pretargeted LS174T tumor-bearing mice. The mice were intravenously injected with [
125
I]I-CC49-TCO (6) 
followed by 2 doses of clearing agent (5) after 30 h and 48 h, 
177
Lu-labeled tetrazines (1a, 1b, 2, 3, or 4) after 
50 h, and euthanasia/biodistribution after 53 h. Data are reported as mean ± SD (P-values refer to comparison 
with lead probe [
177
Lu]4; * P < 0.01; ** P < 0.001). Uptake values for [
125
I]ICC49-TCO (6) in the first column 
are combined data from pretargeting experiments with the new probes (1a, 1b, 2, and 3), detailed data per 
group are reported in Supplemental Table S4. Data for [
177
Lu]4 were published previously [15]. 
Organ 
125
I-CC49-TCO (6) 
n = 13 
[
177
Lu]1a 
n = 4 
[
177
Lu]1b 
n = 3 
[
177
Lu]2 
n = 3 
[
177
Lu]3 
n = 3 
[
177
Lu]4 
n = 4 
 125I (%ID/g) 
177
Lu (%ID/g) 
177
Lu (%ID/g) 
177
Lu (%ID/g) 
177
Lu (%ID/g) 
177
Lu (%ID/g) 
Tumor 20.71 ± 3.37 2.40 ± 0.90* 0.95 ± 0.41** 4.90 ± 0.62 2.72 ± 0.75* 6.13 ± 1.09 
Blood 0.46 ± 0.18 0.11 ± 0.05 0.04 ± 0.01 0.09 ± 0.05 0.05 ± 0.02 0.03 ± 0.01 
Heart 0.57 ± 0.14 0.07 ± 0.02 0.10 ± 0.03 0.06 ± 0.03 0.04 ± 0.01 0.04 ± 0.01 
Lung 0.82 ± 0.18 0.40 ± 0.13 0.18 ± 0.06 0.38 ± 0.05* 0.25 ± 0.02 0.20 ± 0.06 
Liver 1.88 ± 0.76 6.73 ± 1.40** 13.63 ± 1.06** 2.63 ± 0.30** 0.16 ± 0.02 0.18 ± 0.01 
Spleen 0.70 ± 0.19 0.20 ± 0.05* 0.09 ± 0.06 0.11 ± 0.05 0.08 ± 0.02 0.09 ± 0.01 
Kidney 0.49 ± 0.08 1.13 ± 0.16 0.27 ± 0.03** 1.27 ± 0.23 2.72 ± 0.27** 1.23 ± 0.19 
Bladder 1.05 ± 0.29 0.41 ± 0.14 0.13 ± 0.05 1.10 ± 0.54 0.54 ± 0.08 0.54 ± 0.22 
Muscle 0.25 ± 0.05 0.08 ± 0.04 0.14 ± 0.10 0.08 ± 0.06 0.07 ± 0.01* 0.02 ± 0.01 
Bone 0.25 ± 0.06 0.09 ± 0.02 0.04 ± 0.00 0.07 ± 0.04 0.06 ± 0.01 0.05 ± 0.01 
Brain 0.02 ± 0.01 0.01 ± 0.01 0.00 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
 %ID/organ %ID/organ %ID/organ %ID/organ %ID/organ %ID/organ 
Stomach 0.11 ± 0.03 0.06 ± 0.01* 0.08 ± 0.02* 0.07 ± 0.05 0.17 ± 0.05* 0.01 ± 0.01 
Sm. intestine 0.47 ± 0.10 3.84 ± 1.55* 8.53 ± 1.20** 1.05 ± 0.23** 0.92 ± 0.35* 0.08 ± 0.02 
Lg. intestine 0.51 ± 0.13 4.50 ± 1.01** 27.48 ± 2.79** 1.09 ± 0.24* 1.10 ± 0.07** 0.31 ± 0.12 
Thyroid 0.60 ± 0.38 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 
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Table 3 
Biodistribution of 
177
Lu-labeled tetrazines (1a, 1b, 2, and 3) in non-pretargeted mice bearing LS174T colon 
carcinoma xenografts. The mice were intravenously injected with either [
177
Lu]1a, [
177
Lu]1b, [
177
Lu]2, or 
[
177
Lu]3 and euthanized 3 h later. Data are reported as mean ± SD (P-values refer to comparison with the data 
of the same probe in pretargeted mice as provided in Table 2; * P < 0.02; ** P < 0.002).  
Organ 
[
177
Lu]1a 
n = 4 
[
177
Lu]1b 
n = 4 
[
177
Lu]2 
n = 4 
[
177
Lu]3 
n = 4 
 %ID/g %ID/g %ID/g %ID/g 
Tumor 0.64 ± 0.39* 0.06 ± 0.01* 0.55 ± 0.16** 0.38 ± 0.28** 
Blood 0.11 ± 0.06 0.05 ± 0.01 0.08 ± 0.02 0.04 ± 0.01 
Heart 0.08 ± 0.02 0.08 ± 0.01 0.07 ± 0.01 0.03 ± 0.00 
Lung 0.60 ± 0.12 0.15 ± 0.01 0.52 ± 0.03* 0.19 ± 0.04 
Liver 7.91 ± 1.93 12.44 ± 1.69 3.68 ± 0.40* 0.12 ± 0.01* 
Spleen 0.25 ± 0.08 0.11 ± 0.03 0.17 ± 0.04 0.07 ± 0.01 
Kidney 0.10 ± 0.04** 0.30 ± 0.02 2.04 ± 0.18* 2.04 ± 0.31 
Bladder 1.72 ± 0.54* 0.14 ± 0.10 0.27 ± 0.04 0.31 ± 0.18 
Muscle 0.29 ± 0.09* 0.04 ± 0.03 0.05 ± 0.01 0.03 ± 0.02 
Bone 0.05 ± 0.01* 0.05 ± 0.02 0.10 ± 0.01 0.08 ± 0.06 
Brain 0.09 ± 0.02** 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 
 %ID/organ %ID/organ %ID/organ %ID/organ 
Stomach 0.08 ± 0.06 0.10 ± 0.04 0.06 ± 0.02 0.04 ± 0.03* 
Sm. intestine 4.67 ± 1.36 6.34 ± 2.23 1.61 ± 0.55 0.11 ± 0.01* 
Lg. intestine 9.29 ± 1.35** 45.22 ± 3.16** 1.19 ± 0.53 0.96 ± 0.16 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
